RT Journal Article
SR Electronic
T1 Febuxostat Use and Safety in Patients With Hyperuricemia
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.220147
DO 10.3899/jrheum.220147
A1 Kawada, Tomoyuki
YR 2022
UL http://www.jrheum.org/content/early/2022/06/09/jrheum.220147.abstract
AB I read the paper by Deng et al,1 in which the authors conducted a metaanalysis to evaluate whether febuxostat use increased the risk of developing cardiovascular (CV) events, cardiac death, and all-cause mortality. The adjusted relative risk (RR) of febuxostat use for all-cause mortality was 0.87 (95% CI 0.57–1.32).